Omega-3 Marketers Back Down On Comparisons To Amarin's Vascepa
Executive Summary
Coromega Health and Omax will issue press releases explaining that the Amarin study each firm noted in previous releases was not relevant to omega-3 supplements. Releases subject to publication within three days of each settlement's finalization include six mentions of Amarin's Rx prescription triglyceride-lowering fish oil, Vascepa.
You may also be interested in...
US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish
Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.
With Added Indication, Amarin Says Vascepa No ‘Fish Oil’ Like Omega-3s
In Amarin’s “education process” about indication as an add-on to statin therapy to help cut CV risk in high-risk patients, it “will also be emphasizing how Vascepa is different from” Rx drugs fenofibrate and niacin “and omega-3 mixtures,” says CEO John Thero.
Low Doses Caused Failures In Omega-3 Heart Health Studies, Says Dyerberg
In Scientific American opinion piece, omega-3 heart benefit research pioneer Jorn Dyerberg says low doses of omega-3s is the reason many studies evaluating their effectiveness have not found a cause-affect link between their daily use and cardiovascular benefits.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
